Malov, Denmark

Carsten Hoeg-Moller



 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Carsten Hoeg-Moller: Innovator in Pharmaceutical Granulation

Introduction

Carsten Hoeg-Moller is a notable inventor based in Malov, Denmark. He has made significant contributions to the field of pharmaceutical preparations, particularly in the development of granules for solid oral dose medications. With a total of 2 patents, his work has the potential to enhance the efficacy of treatments for various medical conditions.

Latest Patents

Carsten's latest patents focus on improved granular pharmaceutical preparations. These patents disclose advanced methods and apparatus for the production of granules that are especially useful for solid oral dose pharmaceutical preparations. One of the key innovations involves the production of granules comprising 5-aminosalicylic acid (5-ASA), which is used in the treatment of inflammatory bowel disease. The granules produced exhibit a more sharply peaked length distribution and aspect ratio distribution, resulting in a significantly sharper dissolution profile after further processing.

Career Highlights

Carsten Hoeg-Moller is associated with Ferring B.V., a company known for its commitment to advancing healthcare through innovative pharmaceutical solutions. His work at Ferring has allowed him to focus on the development of cutting-edge pharmaceutical technologies that improve patient outcomes.

Collaborations

Throughout his career, Carsten has collaborated with notable colleagues, including Crilles Casper Larsen and Jorgen Wittendorff. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Carsten Hoeg-Moller is a distinguished inventor whose work in pharmaceutical granulation has the potential to significantly impact the treatment of inflammatory bowel disease. His innovative approaches and collaborations continue to drive advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…